Abiopharma

CoyaTherapeutics - Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

New Form 6-K - Sanofi Filed: 2025-10-24 AccNo: 0001121404-25-000026 Size: 1 MB

Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights

New Form 6-K - GSK plc Filed: 2025-10-24 AccNo: 0001654954-25-012159 Size: 2 MB

(99% Neutral) TANGO THERAPEUTICS, INC. (TNGX) Announces Business Combination

New Form 6-K/A - I-Mab Filed: 2025-10-24 AccNo: 0001193125-25-249298 Size: 2 MB

New Form 424B5 - Tango Therapeutics, Inc. Filed: 2025-10-24 AccNo: 0001193125-25-249286 Size: 636 KB

New Form 6-K - Sanofi Filed: 2025-10-24 AccNo: 0001193125-25-249279 Size: 176 KB

Employee Stock Option/ Share Scheme: NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) - OTHER ISSUE OF SECURITIES

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

Waiver: APPLICATION TO ACRA FOR AN EXTENSION OF TIME

Castle Biosciences - New Analysis of 13,560 Patients DemonstratesDecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production